Affinity Asset Advisors, LLC Leap Therapeutics, Inc. Transaction History

Affinity Asset Advisors, LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 14, 2021	SELL	$1.82 - $3.01 $1.65 Million - $2.72 Million	-904,600 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$1.49 - $2.37 $1.35 Million - $2.14 Million	904,600 New	904,600 $2.04 Million

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $288M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.